A glucocerebrosidase gene therapy (PR001) administered into the cisterna magna has been of highest interest for treatment of Gaucher’s disease (NCT04411654, NCT05487599), but will also be evaluated in PD patients with at least one known GBA mutation (NCT04127578). This evidence concerns the gene GBA1 and Parkinson disease.